Cisplatin and Red blood cell count abnormal - a phase IV clinical study of FDA data

Summary:

Red blood cell count abnormal is reported as a side effect among people who take Cisplatin (cisplatin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Taxol, and have Breast cancer female.

The phase IV clinical study analyzes which people have Red blood cell count abnormal when taking Cisplatin. It is created by eHealthMe based on reports of 92,672 people who have side effects when taking Cisplatin from the FDA, and is updated regularly.

What is Cisplatin?

Cisplatin has active ingredients of cisplatin. It is often used in chemotherapy. eHealthMe is studying from 92,837 Cisplatin users. Check the latest studies of Cisplatin.

What is Red blood cell count abnormal?

Red blood cell count abnormal is found to be associated with 216 drugs and 356 conditions by eHealthMe. Check the latest studies of Red blood cell count abnormal.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

92,672 people reported to have side effects when taking Cisplatin.
Among them, 15 people (0.02%) have Red blood cell count abnormal.

Could Cisplatin cause Red blood cell count abnormal?

Among these 15 people:

How long have people been on Cisplatin when they have Red blood cell count abnormal? *

What is the gender of people who have Red blood cell count abnormal when taking Cisplatin? *

female: 78.57 %
male: 21.43 %

What is the age of people who have Red blood cell count abnormal when taking Cisplatin? *

What are other drugs people take besides Cisplatin? *

What are other side effects people have besides Red blood cell count abnormal? *

Nausea (feeling of having an urge to vomit): 8 people, 53.33%
Thrombocytopenia (decrease of platelets in blood): 6 people, 40.00%
Dehydration (dryness resulting from the removal of water): 5 people, 33.33%
White Blood Cell Count Decreased: 4 people, 26.67%
Skin Exfoliation (removal of the oldest dead skin cells): 4 people, 26.67%
Indigestion: 4 people, 26.67%
Nausea And Vomiting: 4 people, 26.67%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 4 people, 26.67%
Full Blood Count Abnormal: 4 people, 26.67%
Weakness: 4 people, 26.67%

What are the existing conditions these people have? *

Neoplasm Malignant (cancer tumour): 4 people, 26.67%
Breast Cancer Metastatic: 4 people, 26.67%
Breast Cancer Female: 4 people, 26.67%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 2 people, 13.33%
Small Cell Lung Cancer Stage Unspecified (lung cancer in unknown stage): 1 person, 6.67%
Ovarian Cancer Stage Iii: 1 person, 6.67%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Cisplatin and have Red blood cell count abnormal?

- Check whether Red blood cell count abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cisplatin:

Cisplatin (92,837 reports)

Browse all side effects of Cisplatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Red blood cell count abnormal:

Red blood cell count abnormal (216 drugs)

Browse all the conditions that are associated with Red blood cell count abnormal:

Red blood cell count abnormal (356 conditions)

Related publications that referenced our studies

Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cisplatin (the active ingredients of Cisplatin) and Cisplatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.